The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.a

Left or biventricular dysfunction/failure

Publications

Karaağaç M, Eryılmaz MK

Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2020;26(3):768-774

Skubitz KM

Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase Inhibitors.

The oncologist. 2019;24(7):e600-e602

Wang H MD, Rodriguez-Pla A MD, Campagna A MD

Rapid and life-threatening heart failure induced by pazopanib.

BMJ case reports. 2018;2018